Abstract
I recently had a discussion with a scientist from a major “Eastern Establishment” pharmaceutical company in the U.S. The topic of our discussion was the success of this young upstart biotechnology industry. Although we were in agreement that biotechnology allows for a more rational approach to design of therapeutic agents, he argued that, “you cannot make it in the pharmaceutical industry simply on injectable hormones”. Whether or not the economic argument is valid, it is clear that widespread, patient-controlled use of therapeutic proteins and peptides demands an alternative to parenteral administration. The most likely route of administration for this relatively new and rapidly expanding class of therapeutic agents is via the nasal cavity. The highly vascularized mucosal surfaces of the nasal passages, the ease of administration, potential advantages of no first pass metabolism and the rapid kinetics of absorption make the nasal route an ideal alternative to parenteral administration. Transnasal systemic drug delivery has become a popular topic (Parr, 1983; Su, 1986) and was the subject of a recently published Symposium held at Rutgers University in New Jersey (Chien, 1985). The message from this meeting was that nasal drug delivery is indeed a viable alternative with significant therapeutic and kinetic advantages, especially for hormones. However, problems of bioavailability, reproducibility of plasma levels and effect on nasal pathology, i.e., local toxicity, remain to be solved.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Reference
Blundell, T.L., Cutfield, J.F., Cutfield, S.M., Dodson, E.J.; Dodson, G.G.; Hodgkin, D.C. and Mercola, D.A., 1972, Three dimensional atomic structure of insulin and its relationship to activity, Diabetes, 21: 492.
Carey, M.C. and Small, D.M.; 1971, Micellar properties of sodium fusidate, a steroid antibiotic structurally resembling the bile salts, J. Lipid Res., 12: 604.
Carey, M.C. and Small, D.M.; 1973 Solution properties of taurine and glycine conjugates of fusidic acid and its derivatives, Biochim et Biophys. Acta 305:51.
Chien, Y.W., 1985 “Transnasal Systemic Medications: Fundamentals, Developmental Concepts and Biomedical Assessments” Elsevier-Amsterdam.
Collens, W.S. and Goldzieher, 1932, Absorption of insulin by nasal mucous membrane, Proc. Soc. Exp. Bio. Med., 29: 756.
Galloway, J.A.; Spradlin, C.T.; Nelson, R.L.; Wentworth, S.M.; Davidson, J.A. and Swarner, J.L. 1981, Factors influencing the absorption, serum insulin concentration, and blood glucose responses after injections of regular insulin and various insulin mixtures. Diabetes Care, 3: 366.
Gansslen, M. 1925. Ueber inhalation van insulin Klin Schnschr 4:71.
Gordon, G.S.; Moses, A.C.; Silver, R.D.; Flier, J.S. and Carey, M.C. 1985, Nasal absorption of insulin: enhancement by hydrophobic bile salts, Proc. Natl. Acad. Sci. USA, 82: 7419.
Hankiss, J. and Hadhazy, C.S., 1958, Resorption von insulin and asthmolysin von der nasenschleimhaut, Acta. Med. Acad. Sci-Hung., 12: 107.
Heubner, W.; de Jough, S.E.; and Laquer, E., 1924, Ueber inhalation von insulin, Klin Schnshr., 3: 2342.
Hirai, S.; Ikenaga, T. and Matsuzawa, T., 1978, Nasal Absorption of insulin in dogs, Diabetes, 27: 296.
Hirai, S.; Yashiki, T.; and Mima, H., 1981, Mechanisms for the enhancement of the nasal absorption of insulin by surfactants, Int. J. Pharm., 9: 173.
Jeffery, P.D., Milthorpe, B.K. and Nichol, L.W., 1976, Polymerization pattern of insulin at ph 7.0, Biochemistry, 15: 4460.
Kimura, T.; Imamura, H.; Hasegawa, K.; and Yoshida, A., 1982 Mechanisims of toxicities of some detergents added to a diet and of the ameliorating effect of dietary fiber in the rat. J. Nut. Sci Vitaminol, 28:483.
Major, R.H., 1936, The intranasal application of insulin, experimental and clinical experiences, Am. J.M. Sci, 192: 257.
Martin, G.P., and Marriott, C, 1981, Membrane damage by bile salts: the protective function of phospholipids, J. Pharm. Pharmacol, 31: 754.
Moses, A.C.; Gordon, G.S.; Carey, M.C. and Flier, J.S., 1983, Insulin administered intranasally as an insulin-bile salt aerosol: effectiveness and reproducibility in normal and diabetic subjects, Diabetes, 32: 1040.
O’Leary, J.F.; Borner, J.w., Runge, W.J. Dehner, L.P. and Goodale, R.L., 1984, Hyperplasia of pancreatic duct epithelium produced by exposure to sodium deoxycholate, Am. J. Surg., 147: 72.
Parr, G.D., 1983, Nasal delivery of drugs, Pharm. Int. Aug:202.
Pontiroli, A.E.; Alberetto, M.;.Secchi, A.S.; Dossi, G.; Bosi, I. and Pozza, G. 1982, Insulin given intranasally induces hypoglycemia in normal and diabetic subjects, Brit, Med. J., 284: 303.
Salzman, R.; Manson, J.E., Griffing, G.T.; Kimmerle, R.; Ruderman, N.; McCall, A.; Stoltz, E.I.; Mullin, C.; Small D.; Armstrong, J. and Melby, J.C., 1985, Intranasal aerosolized insulin: mixed meal studies and long-term use in type I diabetes N. Engl. J. Med., 312: 1078.
Scholmerich, J.; Becher, M.S.; Schmidt, K.; Schubert, R.; Kremer, B.; Feldhaus, S. and Gerok, W., 1984, Influence of hydroxylation and conjugation of bile salts on their membrane damaging properties — studies on isolated hepatoyates and lipid membrane vesicles, Hepatology, 4: 661.
Schubert, R.; Jaroni, H.; Schoelmerich, J. and Schmidt, K.H., 1983, Studies on the mechanism of bile salt-induced liposomal membrane damage, Digestion, 28: 181.
Su, K.S.E.; 1986, Intranasal delivery of peptides and proteins, Pharm. Int., 7: 8.
Whitmore, D.A., Bookes, L.G. and Wheeler, K.P. 1979, Relative effects of different surfactants on intestinal absorption and the release of proteins and phospholipids from the tissue, J. Pharm. Pharmacol, 31: 277.
Woodyatt, R.T., 1922, The clinical use of insulin, J. Metab. Res., 2: 793.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1986 Springer Science+Business Media New York
About this chapter
Cite this chapter
Longenecker, J.P. (1986). NazlinR - Transnasal Systemic Delivery of Insulin. In: Davis, S.S., Illum, L., Tomlinson, E. (eds) Delivery Systems for Peptide Drugs. NATO ASI Series, vol 125. Springer, Boston, MA. https://doi.org/10.1007/978-1-4757-9960-6_17
Download citation
DOI: https://doi.org/10.1007/978-1-4757-9960-6_17
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4757-9962-0
Online ISBN: 978-1-4757-9960-6
eBook Packages: Springer Book Archive